Ivy Rukasha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ivy Rukasha has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Kabelo Gabriel Kaapu
Department of Pathology, School of Medicine, University of Limpopo, Sovenga 0727, Limpopo, South Africa
8 shared publications - Molebogeng Ruth Lekalakala-Mokaba
University of Limpopo
6 shared publications - Emilyn Costa Conceição
Division of Molecular Biology and Human Genetics, South African Medical Research Council Centre for Tuberculosis Research, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 7505, Western Cape, South Africa
3 shared publications Kabelo Gabriel Kaapu
Division of Medical Microbiology, Department of Pathology, School of Medicine, University of Limpopo, Polokwane, South Africa
2 shared publications- Karabo Ramatapa
Department of Pathology, University of Limpopo, Polokwane, South Africa, South Africa
2 shared publications - Mduduzi Paul Mokoena
University of Limpopo
2 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by MDPI AG in Preprints.org
Recent Advances in Aloe vera as a Therapeutic Strategy Against Drug-Resistant Pseudomonas aeruginosa: Phytochemistry, Mechanisms, and Translational Perspectives
Pseudomonas aeruginosa is a major opportunistic pathogen associated with nosocomial infections, antimicrobial resistance, and persistent biofilm formation, highlighting the need for alternative therapeutic strategies. This review critically evaluates the current evidence on the phytochemistry, antimicrobial, antibiofilm, anti-inflammatory, and wound-healing properties of Aloe vera (Aloe barbadensis Mill.) against P. aeruginosa. Relevant peer-reviewed literature from major scientific databases was examined to summarize the phytochemical constituents of A. vera, their proposed mechanisms of action, therapeutic applications, safety considerations, and emerging approaches, including nanotechnology and computational drug discovery. The available evidence indicates that anthraquinones, polysaccharides, flavonoids, and related phytochemicals contribute to antibacterial activity, inhibition of biofilm formation, modulation of host inflammatory responses, and promotion of wound healing. However, considerable variability in phytochemical composition, limited pharmacokinetic and toxicological data, lack of standardized formulations, and insufficient high-quality preclinical and clinical studies continue to hinder clinical translation. Overall, A. vera represents a promising source of adjunctive antimicrobial and anti-virulence compounds for the management of biofilm-associated P. aeruginosa infections. Future research should prioritize phytochemical standardization, mechanistic validation, pharmacokinetic evaluation, and well-designed animal and clinical studies to support the development of safe and clinically effective A. vera-based therapeutics.
- 20 August 2026
- Published by MDPI AG in Preprints.org
Open AccessRecent Advances in Aloe vera as a Therapeutic Strategy Against Drug-Resistant Pseudomonas aeruginosa: Phytochemistry, Mechanisms, and Translational Perspectives
Pseudomonas aeruginosa is a major opportunistic pathogen associated with nosocomial infections, antimicrobial resistance, and persistent biofilm formation, highlighting the need for alternative therapeutic strategies. This review critically evaluates the current evidence on the phytochemistry, antimicrobial, antibiofilm, anti-inflammatory, and wound-healing properties of Aloe vera (Aloe barbadensis Mill.) against P. aeruginosa. Relevant peer-reviewed literature from major scientific databases was examined to summarize the phytochemical constituents of A. vera, their proposed mechanisms of action, therapeutic applications, safety considerations, and emerging approaches, including nanotechnology and computational drug discovery. The available evidence indicates that anthraquinones, polysaccharides, flavonoids, and related phytochemicals contribute to antibacterial activity, inhibition of biofilm formation, modulation of host inflammatory responses, and promotion of wound healing. However, considerable variability in phytochemical composition, limited pharmacokinetic and toxicological data, lack of standardized formulations, and insufficient high-quality preclinical and clinical studies continue to hinder clinical translation. Overall, A. vera represents a promising source of adjunctive antimicrobial and anti-virulence compounds for the management of biofilm-associated P. aeruginosa infections. Future research should prioritize phytochemical standardization, mechanistic validation, pharmacokinetic evaluation, and well-designed animal and clinical studies to support the development of safe and clinically effective A. vera-based therapeutics.
- Open Access
Distribution of Uropathogens and Molecular Characterisation of Virulence Genes of Uropathogenic Escherichia coli (UPEC) in Catheter-Associated Urinary Tract Infections in Limpopo Province, South Africa
Catheter-associated urinary tract infections (CAUTIs) are among the most common nosocomial infections globally and represent a significant cause of morbidity and prolonged hospital stays. There is a scarcity of molecular data regarding pathogens and virulence factors linked to CAUTIs, particularly in South Africa. This study aimed to determine the distribution and frequency of uropathogens, including polymicrobial infection patterns, isolated from catheterised patients at the Polokwane National Health Laboratory Services (NHLS), Limpopo Province, from March 2024 to March 2025, and to characterise the prevalence and co-occurrence of six virulence genes (fimH, papC, sfa, hly, cnf, and aer) among Escherichia coli isolates, the predominant uropathogen identified. Specimens from catheterised patients diagnosed with urinary tract infections at the National Health Laboratory Services in Polokwane were used. Uropathogens were isolated on agar and identified using the VITEK® system. Polymerase chain reaction (PCR) was used for amplification of some virulence genes (fimH, papC, sfa, hly, cnf, and aer) associated with uropathogens. Confirmation of urinary tract infections revealed that Escherichia coli was the predominant uropathogen (32.8%), followed by Klebsiella pneumoniae (17.8%), Enterococcus faecalis, Enterococcus faecium (14%), and others. Among E. coli isolates, virulence gene analysis revealed fimH (79.8%) as the most prevalent, followed by aer (77.4%), sfa (41.7%), hly (27.4%), papC (26.19%), and lastly cnf (9.5%). This study demonstrates that E. coli is the leading cause of CAUTIs in our study population, exhibiting diverse virulence gene combinations that enhance adhesion and overall pathogenicity. The findings emphasise the need for routine molecular surveillance of CAUTI pathogens, reinforcement of catheter-care protocols, and targeted infection prevention strategies.
Open AccessDistribution of Uropathogens and Molecular Characterisation of Virulence Genes of Uropathogenic Escherichia coli (UPEC) in Catheter-Associated Urinary Tract Infections in Limpopo Province, South Africa
Catheter-associated urinary tract infections (CAUTIs) are among the most common nosocomial infections globally and represent a significant cause of morbidity and prolonged hospital stays. There is a scarcity of molecular data regarding pathogens and virulence factors linked to CAUTIs, particularly in South Africa. This study aimed to determine the distribution and frequency of uropathogens, including polymicrobial infection patterns, isolated from catheterised patients at the Polokwane National Health Laboratory Services (NHLS), Limpopo Province, from March 2024 to March 2025, and to characterise the prevalence and co-occurrence of six virulence genes (fimH, papC, sfa, hly, cnf, and aer) among Escherichia coli isolates, the predominant uropathogen identified. Specimens from catheterised patients diagnosed with urinary tract infections at the National Health Laboratory Services in Polokwane were used. Uropathogens were isolated on agar and identified using the VITEK® system. Polymerase chain reaction (PCR) was used for amplification of some virulence genes (fimH, papC, sfa, hly, cnf, and aer) associated with uropathogens. Confirmation of urinary tract infections revealed that Escherichia coli was the predominant uropathogen (32.8%), followed by Klebsiella pneumoniae (17.8%), Enterococcus faecalis, Enterococcus faecium (14%), and others. Among E. coli isolates, virulence gene analysis revealed fimH (79.8%) as the most prevalent, followed by aer (77.4%), sfa (41.7%), hly (27.4%), papC (26.19%), and lastly cnf (9.5%). This study demonstrates that E. coli is the leading cause of CAUTIs in our study population, exhibiting diverse virulence gene combinations that enhance adhesion and overall pathogenicity. The findings emphasise the need for routine molecular surveillance of CAUTI pathogens, reinforcement of catheter-care protocols, and targeted infection prevention strategies.
- Open Access
- 22 July 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (7) , 1596
Diagnostic Discordance During MDR-TB Treatment: Retrospective Identification of Mycobacterium avium Complex-Associated Nontuberculous Mycobacterium by Whole-Genome Sequencing
Nontuberculous mycobacteria (NTM) pose significant diagnostic challenges in high tuberculosis (TB)-burden settings, particularly when routine molecular assays suggest multidrug-resistant TB (MDR-TB). Current diagnostic algorithms in high TB-burden settings are primarily designed to detect members of the Mycobacterium tuberculosiscomplex (MTBC) and may inadequately distinguish NTM when discordant laboratory findings are encountered. The value of this case lies not in demonstrating that whole-genome sequencing (WGS) should guide real-time treatment, but in illustrating how diagnostic uncertainty can arise when routine MTBC-focused tests fail to identify NTM and how genomic surveillance can contribute to species-level characterization in such settings. We report a complex case which was initially diagnosed as rifampicin- and isoniazid-resistant MTBC and subsequently managed according to programmatic MDR-TB guidelines. Persistent acid-fast bacilli positivity in the presence of negative MTBC antigen testing during follow-up raised suspicion of NTM involvement. Whole-genome sequencing (WGS), performed retrospectively on a follow-up isolate, identified an NTM belonging to the Mycobacterium avium complex (MAC) which was phylogenetically closest to genomes provisionally designated Mycobacterium europaeum_A and distinct from Mycobacterium europaeum sensu stricto, a member of the Mycobacterium simiae complex. The identification of a MAC-associated NTM provided an explanation for the observed diagnostic discordance but could not determine whether the organism represented colonization, sequential infection, or concurrent infection. Although WGS did not inform clinical management, it provided high-resolution species identification and highlighted important limitations of MTBC-focused diagnostic workflows when discordant microbiological findings are encountered. This case underscores the need for the targeted investigation of NTM in patients with acid-fast bacilli-positive cultures and negative MTBC antigen testing and supports the use of genomic surveillance to improve species-level identification and understanding of NTM epidemiology in high TB-burden settings such as Limpopo Province, South Africa.
- 22 July 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (7) , 1596
Open AccessDiagnostic Discordance During MDR-TB Treatment: Retrospective Identification of Mycobacterium avium Complex-Associated Nontuberculous Mycobacterium by Whole-Genome Sequencing
Nontuberculous mycobacteria (NTM) pose significant diagnostic challenges in high tuberculosis (TB)-burden settings, particularly when routine molecular assays suggest multidrug-resistant TB (MDR-TB). Current diagnostic algorithms in high TB-burden settings are primarily designed to detect members of the Mycobacterium tuberculosiscomplex (MTBC) and may inadequately distinguish NTM when discordant laboratory findings are encountered. The value of this case lies not in demonstrating that whole-genome sequencing (WGS) should guide real-time treatment, but in illustrating how diagnostic uncertainty can arise when routine MTBC-focused tests fail to identify NTM and how genomic surveillance can contribute to species-level characterization in such settings. We report a complex case which was initially diagnosed as rifampicin- and isoniazid-resistant MTBC and subsequently managed according to programmatic MDR-TB guidelines. Persistent acid-fast bacilli positivity in the presence of negative MTBC antigen testing during follow-up raised suspicion of NTM involvement. Whole-genome sequencing (WGS), performed retrospectively on a follow-up isolate, identified an NTM belonging to the Mycobacterium avium complex (MAC) which was phylogenetically closest to genomes provisionally designated Mycobacterium europaeum_A and distinct from Mycobacterium europaeum sensu stricto, a member of the Mycobacterium simiae complex. The identification of a MAC-associated NTM provided an explanation for the observed diagnostic discordance but could not determine whether the organism represented colonization, sequential infection, or concurrent infection. Although WGS did not inform clinical management, it provided high-resolution species identification and highlighted important limitations of MTBC-focused diagnostic workflows when discordant microbiological findings are encountered. This case underscores the need for the targeted investigation of NTM in patients with acid-fast bacilli-positive cultures and negative MTBC antigen testing and supports the use of genomic surveillance to improve species-level identification and understanding of NTM epidemiology in high TB-burden settings such as Limpopo Province, South Africa.
- Open Access
- 1 June 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-13
Diagnostic Accuracy of the Biofire FilmArray Blood Culture Identification 2 (BCID2) for Bloodstream Infections in Limpopo, South Africa
Background: Bloodstream infections are a leading global cause of mortality and morbidity. Timely and accurate diagnosis improves outcomes, especially in resource-limited settings. Rapid and accurate diagnostic tools are essential for effective treatment, particularly in resource-limited settings. Our study aimed to evaluate the diagnostic performance of the BCID2 assay, comparing its effectiveness to the VITEK2 at a routine lab in Limpopo, South Africa, where alternative assays are necessary to overcome resource unavailability in areas located further away from major laboratories. Methods: This cross-sectional study was conducted from August to December 2023. A total of 247 positive blood culture bottles were tested using both BCID2 and VITEK2 systems. Statistical analysis, including specificity, sensitivity, and accuracy, was calculated using Medcalc and SPSS. Results: The BCID2 panel demonstrated a sensitivity, specificity, and accuracy of 95.7%, 95.5%, and 96%, respectively. Of the samples, 72% (179/247) were monomicrobial and 28% (68/247) were polymicrobial, with a total of 16 off-panel microorganisms identified across both groups. blaCTX-M was the most frequent Gram-negative resistance gene detected (55.2%, 80/145), while blaVIM was the least common (0.7%, 1/145). Conclusion: The study concluded that the BCID2 assay demonstrates excellent diagnostic accuracy, with sensitivity, specificity, and overall accuracy rates above 95%. Its ability to rapidly detect bloodstream infections and antimicrobial resistance markers makes it a highly effective tool, particularly in resource-limited settings like Limpopo, South Africa, where timely and accurate diagnosis is crucial to improving patient outcomes.
- 1 June 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-13
Open AccessDiagnostic Accuracy of the Biofire FilmArray Blood Culture Identification 2 (BCID2) for Bloodstream Infections in Limpopo, South Africa
Background: Bloodstream infections are a leading global cause of mortality and morbidity. Timely and accurate diagnosis improves outcomes, especially in resource-limited settings. Rapid and accurate diagnostic tools are essential for effective treatment, particularly in resource-limited settings. Our study aimed to evaluate the diagnostic performance of the BCID2 assay, comparing its effectiveness to the VITEK2 at a routine lab in Limpopo, South Africa, where alternative assays are necessary to overcome resource unavailability in areas located further away from major laboratories. Methods: This cross-sectional study was conducted from August to December 2023. A total of 247 positive blood culture bottles were tested using both BCID2 and VITEK2 systems. Statistical analysis, including specificity, sensitivity, and accuracy, was calculated using Medcalc and SPSS. Results: The BCID2 panel demonstrated a sensitivity, specificity, and accuracy of 95.7%, 95.5%, and 96%, respectively. Of the samples, 72% (179/247) were monomicrobial and 28% (68/247) were polymicrobial, with a total of 16 off-panel microorganisms identified across both groups. blaCTX-M was the most frequent Gram-negative resistance gene detected (55.2%, 80/145), while blaVIM was the least common (0.7%, 1/145). Conclusion: The study concluded that the BCID2 assay demonstrates excellent diagnostic accuracy, with sensitivity, specificity, and overall accuracy rates above 95%. Its ability to rapidly detect bloodstream infections and antimicrobial resistance markers makes it a highly effective tool, particularly in resource-limited settings like Limpopo, South Africa, where timely and accurate diagnosis is crucial to improving patient outcomes.
- Open Access
- 28 May 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (6) , 543
Resistance to Linezolid and Pretomanid in the Era of Modern Drug-Resistant Tuberculosis Treatment in South Africa: A Systematic Review and Meta-Analysis
Background: The success of modern drug-resistant tuberculosis (DR-TB) regimens increasingly depends on linezolid (LZD) and pretomanid (Pa), yet the emergence of resistance to these critical agents threatens to reverse recent treatment advances, with limited consolidated evidence available from high-burden settings such as South Africa. Objectives: To systematically review and meta-analyse South African data on LZD and Pa resistance, minimum inhibitory concentrations (MICs), resistance-associated mutations, and treatment outcomes. Eligibility Criteria: We included clinical trials, cohort studies, surveillance studies, and molecular investigations conducted in South Africa from 2013 onward that reported resistance prevalence, MIC data, genotypic mutations, or treatment outcomes related to LZD and/or Pa. Information Sources: PubMed, PubMed, Embase, Web of Science, and grey literature sources were searched from January 2013 to 31 December 2025 in accordance with PRISMA 2020 guidelines. Risk of Bias: Study quality was assessed using the Joanna Briggs Institute (JBI) cohort appraisal checklist. Included Studies: Seventeen studies representing provincial and national cohorts were included. Synthesis of Results: Random-effects meta-analysis was used to estimate pooled baseline resistance. Subgroup, sensitivity, and meta-regression analyses were performed. Results: Random-effects meta-analysis demonstrated a pooled baseline LZD resistance prevalence of 0.53% (95% CI: 0.01–1.83; I2 = 81.1%) in routine South African cohorts, while substantially higher resistance (33%) was observed in treatment-failure populations. Baseline LZD MICs were typically 0.125–1.0 µg/mL, while elevated MICs (up to 8.0 µg/mL) were associated with rplC and rrl mutations, particularly rplC Cys154Arg. No confirmed phenotypic Pa resistance was identified across included South African cohorts, despite the detection of resistance-associated mutations in genomic surveillance studies. MIC values remained within the range of 0.016–1.0 µg/mL. Mutations in ddn, fbiA, fbiC, and fgd1 were reported in genomic studies. Treatment success rates ranged from 63.6% to 99% for LZD-containing regimens and approached 90% for Pa-based regimens. Limitations: Limited study numbers, heterogeneity in laboratory methods, and overrepresentation of certain provinces may affect generalizability. Conclusions: Baseline resistance to LZD and Pa in South Africa remains low, supporting continued programmatic use. Ongoing molecular surveillance is essential to detect resistance amplification and preserve regimen efficacy.
- 28 May 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (6) , 543
Open AccessResistance to Linezolid and Pretomanid in the Era of Modern Drug-Resistant Tuberculosis Treatment in South Africa: A Systematic Review and Meta-Analysis
Background: The success of modern drug-resistant tuberculosis (DR-TB) regimens increasingly depends on linezolid (LZD) and pretomanid (Pa), yet the emergence of resistance to these critical agents threatens to reverse recent treatment advances, with limited consolidated evidence available from high-burden settings such as South Africa. Objectives: To systematically review and meta-analyse South African data on LZD and Pa resistance, minimum inhibitory concentrations (MICs), resistance-associated mutations, and treatment outcomes. Eligibility Criteria: We included clinical trials, cohort studies, surveillance studies, and molecular investigations conducted in South Africa from 2013 onward that reported resistance prevalence, MIC data, genotypic mutations, or treatment outcomes related to LZD and/or Pa. Information Sources: PubMed, PubMed, Embase, Web of Science, and grey literature sources were searched from January 2013 to 31 December 2025 in accordance with PRISMA 2020 guidelines. Risk of Bias: Study quality was assessed using the Joanna Briggs Institute (JBI) cohort appraisal checklist. Included Studies: Seventeen studies representing provincial and national cohorts were included. Synthesis of Results: Random-effects meta-analysis was used to estimate pooled baseline resistance. Subgroup, sensitivity, and meta-regression analyses were performed. Results: Random-effects meta-analysis demonstrated a pooled baseline LZD resistance prevalence of 0.53% (95% CI: 0.01–1.83; I2 = 81.1%) in routine South African cohorts, while substantially higher resistance (33%) was observed in treatment-failure populations. Baseline LZD MICs were typically 0.125–1.0 µg/mL, while elevated MICs (up to 8.0 µg/mL) were associated with rplC and rrl mutations, particularly rplC Cys154Arg. No confirmed phenotypic Pa resistance was identified across included South African cohorts, despite the detection of resistance-associated mutations in genomic surveillance studies. MIC values remained within the range of 0.016–1.0 µg/mL. Mutations in ddn, fbiA, fbiC, and fgd1 were reported in genomic studies. Treatment success rates ranged from 63.6% to 99% for LZD-containing regimens and approached 90% for Pa-based regimens. Limitations: Limited study numbers, heterogeneity in laboratory methods, and overrepresentation of certain provinces may affect generalizability. Conclusions: Baseline resistance to LZD and Pa in South Africa remains low, supporting continued programmatic use. Ongoing molecular surveillance is essential to detect resistance amplification and preserve regimen efficacy.
- Open Access
- 13 April 2026
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 11 (4) , 100
Epidemiological Characteristics and Treatment Outcomes of Drug-Resistant Tuberculosis in Limpopo Province, South Africa (2020–2024)
Background: Drug-resistant tuberculosis (DR-TB) continues to pose a major challenge in Limpopo Province, a predominantly rural region of South Africa with high prevalence of HIV and mobility of the cross-border population. Despite the scale-up of short all-oral bedaquiline-based regimens, there is limited recent provincial evidence describing DR-TB epidemiological characteristics and treatment outcomes in the post-COVID-19 period. This study aimed to assess resistance patterns, treatment outcomes, and factors associated with unfavorable outcomes among patients with DR-TB in Limpopo Province from 2020 to 2024. Methods: A retrospective cohort study was conducted using routinely collected data from the Electronic Drug Resistant Tuberculosis Register (EDRWeb). All laboratory-confirmed DR-TB cases diagnosed between January 2020 and December 2024 were included. Descriptive statistics were used to summarize demographic and clinical characteristics. Multivariable logistic regression was performed to identify predictors of unfavorable outcomes (treatment failure, death, and loss to follow-up). Kaplan–Meier survival analysis was used to estimate survival probability following treatment initiation. Results: A total of 1240 DR-TB cases were recorded, of which 1165 (94%) had documented treatment outcomes. Rifampicin-resistant TB (RR-TB) predominated throughout the study period, accounting for 76% (951/1240) of cases and remaining stable over time. Treatment success improved from 173/260 (67%) in 2020 to 130/166 (78%) in 2024, while loss to follow-up declined from 34/260 (13%) to 4/166 (2%). Kaplan–Meier survival analysis showed that mortality occurred predominantly during the early phase of treatment. Patients receiving bedaquiline-containing regimens demonstrated significantly higher survival probability compared with those not receiving bedaquiline (log-rank p = 0.024; HR 0.58, 95% CI: 0.35–0.94). In multivariable analysis, HIV infection was independently associated with unfavorable outcomes (aOR 1.36; 95% CI: 1.04–1.77; p = 0.025), while increasing age showed a modest association with poorer outcomes. Conclusions: Treatment outcomes for DR-TB improved over the study period, accompanied by declining loss to follow-up and improved survival. The survival advantage observed among patients receiving bedaquiline-containing regimens supports continued prioritization of bedaquiline-based treatment strategies in DR-TB management. Strengthening access to these regimens, alongside integrated HIV care, may further improve treatment outcomes in Limpopo Province and similar high-burden settings in South Africa.
- 13 April 2026
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 11 (4) , 100
Open AccessEpidemiological Characteristics and Treatment Outcomes of Drug-Resistant Tuberculosis in Limpopo Province, South Africa (2020–2024)
Background: Drug-resistant tuberculosis (DR-TB) continues to pose a major challenge in Limpopo Province, a predominantly rural region of South Africa with high prevalence of HIV and mobility of the cross-border population. Despite the scale-up of short all-oral bedaquiline-based regimens, there is limited recent provincial evidence describing DR-TB epidemiological characteristics and treatment outcomes in the post-COVID-19 period. This study aimed to assess resistance patterns, treatment outcomes, and factors associated with unfavorable outcomes among patients with DR-TB in Limpopo Province from 2020 to 2024. Methods: A retrospective cohort study was conducted using routinely collected data from the Electronic Drug Resistant Tuberculosis Register (EDRWeb). All laboratory-confirmed DR-TB cases diagnosed between January 2020 and December 2024 were included. Descriptive statistics were used to summarize demographic and clinical characteristics. Multivariable logistic regression was performed to identify predictors of unfavorable outcomes (treatment failure, death, and loss to follow-up). Kaplan–Meier survival analysis was used to estimate survival probability following treatment initiation. Results: A total of 1240 DR-TB cases were recorded, of which 1165 (94%) had documented treatment outcomes. Rifampicin-resistant TB (RR-TB) predominated throughout the study period, accounting for 76% (951/1240) of cases and remaining stable over time. Treatment success improved from 173/260 (67%) in 2020 to 130/166 (78%) in 2024, while loss to follow-up declined from 34/260 (13%) to 4/166 (2%). Kaplan–Meier survival analysis showed that mortality occurred predominantly during the early phase of treatment. Patients receiving bedaquiline-containing regimens demonstrated significantly higher survival probability compared with those not receiving bedaquiline (log-rank p = 0.024; HR 0.58, 95% CI: 0.35–0.94). In multivariable analysis, HIV infection was independently associated with unfavorable outcomes (aOR 1.36; 95% CI: 1.04–1.77; p = 0.025), while increasing age showed a modest association with poorer outcomes. Conclusions: Treatment outcomes for DR-TB improved over the study period, accompanied by declining loss to follow-up and improved survival. The survival advantage observed among patients receiving bedaquiline-containing regimens supports continued prioritization of bedaquiline-based treatment strategies in DR-TB management. Strengthening access to these regimens, alongside integrated HIV care, may further improve treatment outcomes in Limpopo Province and similar high-burden settings in South Africa.
- Open Access
- 10 April 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (4) , 385
Bedaquiline Resistance in Drug-Resistant Tuberculosis in South Africa: A Systematic Review and Meta-Analysis of Emerging Trends
Background: Bedaquiline (BDQ) resistance poses a serious threat to its long-term efficacy, particularly in high-burden settings like South Africa, where data remain scattered and largely non-synthesized. Objective: This study aimed to estimate the trends of BDQ resistance in drug resistant tuberculosis (DR-TB), characterize associated resistance mechanisms, and evaluate implications for treatment outcomes in South Africa. Eligibility criteria: We included primary studies reporting BDQ resistance, resistance mechanisms, minimum inhibitory concentrations (MICs), or treatment outcomes among patients with MDR- or XDR-TB treated with BDQ-containing regimens in South Africa. Information sources: PubMed, Web of Science, and Embase were searched for studies published between January 2016 and July 2024. Risk of bias: Study quality was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist. Synthesis of results: Random-effects meta-analysis with Freeman–Tukey double-arcsine transformation was used to estimate pooled BDQ resistance prevalence. Heterogeneity, sensitivity analyses, and publication bias were assessed. Results: Twenty-eight studies were included. The pooled prevalence of BDQ resistance was 6.0% (95% CI: 4.1–7.9%; I2 = 62%). Treatment success averaged 63.5%, and culture conversion reached 84.1%. Resistance-associated mutations were most frequently reported in Rv0678, followed by atpE and pepQ, often associated with elevated MICs (≥2–4 μg/mL). Evidence of small-study effects was observed (Egger’s test, p = 0.0012). A pooled prevalence estimate was calculated; however, evidence of small-study effects suggests that estimates should be interpreted cautiously. Limitations: Heterogeneity in study design, outcome definitions, and resistance testing methods limited comparability across studies. Conclusions: Bedaquiline remains effective for DR-TB treatment in South Africa; however, emerging resistance and its molecular drivers pose a growing threat to regimen sustainability, including BPaL. Strengthened surveillance and standardized resistance testing are urgently needed.
- 10 April 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (4) , 385
Open AccessBedaquiline Resistance in Drug-Resistant Tuberculosis in South Africa: A Systematic Review and Meta-Analysis of Emerging Trends
Background: Bedaquiline (BDQ) resistance poses a serious threat to its long-term efficacy, particularly in high-burden settings like South Africa, where data remain scattered and largely non-synthesized. Objective: This study aimed to estimate the trends of BDQ resistance in drug resistant tuberculosis (DR-TB), characterize associated resistance mechanisms, and evaluate implications for treatment outcomes in South Africa. Eligibility criteria: We included primary studies reporting BDQ resistance, resistance mechanisms, minimum inhibitory concentrations (MICs), or treatment outcomes among patients with MDR- or XDR-TB treated with BDQ-containing regimens in South Africa. Information sources: PubMed, Web of Science, and Embase were searched for studies published between January 2016 and July 2024. Risk of bias: Study quality was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist. Synthesis of results: Random-effects meta-analysis with Freeman–Tukey double-arcsine transformation was used to estimate pooled BDQ resistance prevalence. Heterogeneity, sensitivity analyses, and publication bias were assessed. Results: Twenty-eight studies were included. The pooled prevalence of BDQ resistance was 6.0% (95% CI: 4.1–7.9%; I2 = 62%). Treatment success averaged 63.5%, and culture conversion reached 84.1%. Resistance-associated mutations were most frequently reported in Rv0678, followed by atpE and pepQ, often associated with elevated MICs (≥2–4 μg/mL). Evidence of small-study effects was observed (Egger’s test, p = 0.0012). A pooled prevalence estimate was calculated; however, evidence of small-study effects suggests that estimates should be interpreted cautiously. Limitations: Heterogeneity in study design, outcome definitions, and resistance testing methods limited comparability across studies. Conclusions: Bedaquiline remains effective for DR-TB treatment in South Africa; however, emerging resistance and its molecular drivers pose a growing threat to regimen sustainability, including BPaL. Strengthened surveillance and standardized resistance testing are urgently needed.
- Open Access
- 1 January 2026
- Published by AOSIS in The Journal of Medical Laboratory Science and Technology of South Africa
- Vol. 8 (1) , 8
Comparative evaluation of the Xpert MTB/XDR and FluoroType XDR assays for detecting fluoroquinolone resistance in multidrug-resistant tuberculosis clinical isolates
Background: Accurate detection of fluoroquinolone (FLQ) resistance in multidrug-resistant tuberculosis (MDR-TB) is essential for effective treatment. Aim: To compare Xpert MTB/XDR and FluoroType XDR for detecting FLQ resistance in MDR-TB. Setting: National Health Laboratory Service diagnostic laboratory, Polokwane, South Africa. Methods: Seventy-eight MDR-TB isolates collected from January 2024 to July 2024 were tested using Xpert MTB/XDR, FluoroType XDR and GenoType MTBDRsl line probe assay (LPA) as the reference standard. Whole-genome sequencing (WGS) data from 35 isolates were used to resolve discordant results. Diagnostic accuracy and agreement were assessed using sensitivity, specificity and Cohen’s kappa. Results: Xpert MTB/XDR showed 97.7% sensitivity (95% confidence interval [CI]: 87.9–99.8) and 100.0% specificity (95% CI: 89.7–100.0). FluoroType XDR showed 100.0% sensitivity (95% CI: 90.6–100.0) and 97.2% specificity (95% CI: 85.5–99.9), with five indeterminate results. Compared directly with Xpert, FluoroType showed 94.9% sensitivity and 100.0% specificity. Agreement was strong (κ = 0.95; 95% CI: 0.88–1.00). WGS resolved two discordant cases: one resistant isolate with a *gyrA* Asp94Gly mutation and one susceptible isolate without resistance-associated mutations. Conclusion: Both assays performed well for FLQ resistance detection. FluoroType XDR showed higher sensitivity but more indeterminate results. Strong assay agreement and WGS resolution of discordances support their use in MDR-TB diagnostics. Contribution: This study demonstrates strong concordance between Xpert MTB/XDR and FluoroType XDR for FLQ resistance detection and highlights the value of WGS in resolving discordant results.
- 1 January 2026
- Published by AOSIS in The Journal of Medical Laboratory Science and Technology of South Africa
- Vol. 8 (1) , 8
Open AccessComparative evaluation of the Xpert MTB/XDR and FluoroType XDR assays for detecting fluoroquinolone resistance in multidrug-resistant tuberculosis clinical isolates
Background: Accurate detection of fluoroquinolone (FLQ) resistance in multidrug-resistant tuberculosis (MDR-TB) is essential for effective treatment. Aim: To compare Xpert MTB/XDR and FluoroType XDR for detecting FLQ resistance in MDR-TB. Setting: National Health Laboratory Service diagnostic laboratory, Polokwane, South Africa. Methods: Seventy-eight MDR-TB isolates collected from January 2024 to July 2024 were tested using Xpert MTB/XDR, FluoroType XDR and GenoType MTBDRsl line probe assay (LPA) as the reference standard. Whole-genome sequencing (WGS) data from 35 isolates were used to resolve discordant results. Diagnostic accuracy and agreement were assessed using sensitivity, specificity and Cohen’s kappa. Results: Xpert MTB/XDR showed 97.7% sensitivity (95% confidence interval [CI]: 87.9–99.8) and 100.0% specificity (95% CI: 89.7–100.0). FluoroType XDR showed 100.0% sensitivity (95% CI: 90.6–100.0) and 97.2% specificity (95% CI: 85.5–99.9), with five indeterminate results. Compared directly with Xpert, FluoroType showed 94.9% sensitivity and 100.0% specificity. Agreement was strong (κ = 0.95; 95% CI: 0.88–1.00). WGS resolved two discordant cases: one resistant isolate with a *gyrA* Asp94Gly mutation and one susceptible isolate without resistance-associated mutations. Conclusion: Both assays performed well for FLQ resistance detection. FluoroType XDR showed higher sensitivity but more indeterminate results. Strong assay agreement and WGS resolution of discordances support their use in MDR-TB diagnostics. Contribution: This study demonstrates strong concordance between Xpert MTB/XDR and FluoroType XDR for FLQ resistance detection and highlights the value of WGS in resolving discordant results.
- Open Access
- 1 January 2026
- Published by AOSIS in African Journal of Primary Health Care & Family Medicine
- Vol. 19 (1) , 8-e8
Diagnostic performance of the FluoroType MTBDR assay for rifampicin and isoniazid resistance in routine laboratory setting
Background: Drug-resistant tuberculosis (DR-TB) continues to be a major public health threat, especially in high-burden settings like South Africa. Rapid and accurate diagnosis of resistance to rifampicin (RIF) and isoniazid (INH) is essential to ensure that patients receive the right treatment as early as possible. Current diagnostic tools, though effective, have limitations. This study addresses the urgent need for faster, reliable alternatives to improve DR-TB detection. Aim: The aim of this study is to assess the performance of the FluoroType MTBDR assay in detecting resistance to RIF and INH in a real-world diagnostic setting. Setting: The study was carried out at the National Health Laboratory Services (NHLS) Polokwane Laboratory, a routine laboratory in Limpopo province, South Africa. Methods: We tested 152 Mycobacterium tuberculosis (MTB) isolates collected from the 2023 laboratory repository using the FluoroType MTBDR version 2 assay. These results were compared with those from two established methods: GenoType MTBDRplus and Xpert MTB/RIF Ultra. Whole genome sequencing (WGS) was used to resolve any discrepancies, serving as the reference standard. Diagnostic accuracy was evaluated using sensitivity, specificity and predictive values. Results: Of the 152 isolates, 65% were drug-resistant. FluoroType MTBDR showed excellent performance – 100% specificity and 96% sensitivity for RIF resistance and 91% sensitivity and 99% specificity for INH resistance – competing with the GenoType MTBDRplus. Conclusion: FluoroType MTBDR offers a reliable, rapid alternative for detecting DR-TB, with the potential to improve timely diagnosis and treatment. Contribution: This study highlights the FluoroType MTBDR assay as a valuable diagnostic tool for routine use, contributing to improved TB control strategies, especially in resource-limited, high-burden settings, consistent with the journal’s scope.
- 1 January 2026
- Published by AOSIS in African Journal of Primary Health Care & Family Medicine
- Vol. 19 (1) , 8-e8
Open AccessDiagnostic performance of the FluoroType MTBDR assay for rifampicin and isoniazid resistance in routine laboratory setting
Background: Drug-resistant tuberculosis (DR-TB) continues to be a major public health threat, especially in high-burden settings like South Africa. Rapid and accurate diagnosis of resistance to rifampicin (RIF) and isoniazid (INH) is essential to ensure that patients receive the right treatment as early as possible. Current diagnostic tools, though effective, have limitations. This study addresses the urgent need for faster, reliable alternatives to improve DR-TB detection. Aim: The aim of this study is to assess the performance of the FluoroType MTBDR assay in detecting resistance to RIF and INH in a real-world diagnostic setting. Setting: The study was carried out at the National Health Laboratory Services (NHLS) Polokwane Laboratory, a routine laboratory in Limpopo province, South Africa. Methods: We tested 152 Mycobacterium tuberculosis (MTB) isolates collected from the 2023 laboratory repository using the FluoroType MTBDR version 2 assay. These results were compared with those from two established methods: GenoType MTBDRplus and Xpert MTB/RIF Ultra. Whole genome sequencing (WGS) was used to resolve any discrepancies, serving as the reference standard. Diagnostic accuracy was evaluated using sensitivity, specificity and predictive values. Results: Of the 152 isolates, 65% were drug-resistant. FluoroType MTBDR showed excellent performance – 100% specificity and 96% sensitivity for RIF resistance and 91% sensitivity and 99% specificity for INH resistance – competing with the GenoType MTBDRplus. Conclusion: FluoroType MTBDR offers a reliable, rapid alternative for detecting DR-TB, with the potential to improve timely diagnosis and treatment. Contribution: This study highlights the FluoroType MTBDR assay as a valuable diagnostic tool for routine use, contributing to improved TB control strategies, especially in resource-limited, high-burden settings, consistent with the journal’s scope.
- Open Access
- 24 November 2025
- Published by MDPI AG in Proceedings
- Vol. 130 (1) , 24
Computational and Experimental Validation of Aloe Vera Against Pseudomonas Aeruginosa PsrA in Interventive Antibacterial Therapeutics
Background: Pseudomonas aeruginosa, a multidrug-resistant pathogen, employs biofilm formation as a key virulence strategy, complicating treatment
- 24 November 2025
- Published by MDPI AG in Proceedings
- Vol. 130 (1) , 24
Open AccessComputational and Experimental Validation of Aloe Vera Against Pseudomonas Aeruginosa PsrA in Interventive Antibacterial Therapeutics
Background: Pseudomonas aeruginosa, a multidrug-resistant pathogen, employs biofilm formation as a key virulence strategy, complicating treatment